mortality/aging
• upon withdrawal of tetracycline (TET), expression of BCR/ABL results in development of lethal leukemia; 100% of bitransgenic mice die by ~76 days
|
hematopoietic system
• spleen becomes massively enlarged when TET treatment is stopped
|
• severe thrombocytopenia in peripheral blood develops when TET treatment is stopped
|
• increased peripheral blood leukocyte count is observed 10-20 days after TET withdrawal; blood shows presence of cells resembling immature lymphocytes
• when TET is given to mice in advanced stages of disease, WBC counts normalize in 48-72 hours, lymphoblasts are not detected in peripheral blood
|
immune system
• spleen becomes massively enlarged when TET treatment is stopped
|
• increased peripheral blood leukocyte count is observed 10-20 days after TET withdrawal; blood shows presence of cells resembling immature lymphocytes
• when TET is given to mice in advanced stages of disease, WBC counts normalize in 48-72 hours, lymphoblasts are not detected in peripheral blood
|
• nodes become massively enlarged when TET is stopped; when TET is given to mice in advanced stages of disease, complete regression of enlarged lymph nodes occurs within 5 days
|
cellular
• resumption of TET treatment results in ~80% of leukemic cells undergoing apoptosis
|
skeleton
• bone marrow is pale; hematopoietic cells are replaced by lymphoblasts
|
neoplasm
• 100% of mice develop acute lymphoblastic leukemia (ALL) upon withdrawal of tetracycline administration
• leukocyte counts range from 80000-150000/ul
• leukemic cells infiltrate skin, pleura, and meninges
|
growth/size/body
• spleen becomes massively enlarged when TET treatment is stopped
|